Mainstream

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Post ContentxgnRead More

You might also be interested in reading International Chess Federation Checks Into Web3 With Avalanche Integration.

July 29, 2025
In Mainstream